Drugs / ADR-002K
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04695522 | Nov 2019 → Apr 2021 | — | Osaka University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07192211 | Apr 2026 → Sep 2028 expected | ischemic disease | Rohto Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADR-002K | “ADR-002K (Adipose-derived mesenchymal stem cells) is administered to the surface of the heart” NCT07192211 ↗ |
| Modality | Cell therapy | “Adipose-derived stem cells (ADSCs)” PMID 39623426 ↗ Dec 2024 |
| Route | Other | “ADSC spray therapy” PMID 39623426 ↗ Dec 2024 |